| Literature DB >> 33080054 |
Zhengyu Zhu1, LinLin Xu1, DeYan Cao1, ChaoYuan Song2, YuZhen Wang3, Maoyu Li1, Jieke Yan4, ZhaoHong Xie1.
Abstract
Mitochondrial dysfunction plays a key role in the pathogenesis and progression of Alzheimer's Disease (AD). Our previous studies showed that over expression of AD-associated mutant β-amyloid precursor protein (APP) led to abnormalities of mitochondrial biogenesis and mitophagy, leading to mitochondrial dysfunction. However, the mechanism remains unclear. In this study, we investigated the effect of orexin-A on mitochondrial biogenesis, mitophagy and mitochondrial structure in overexpression of AD-associated mutant APP cells. We used 20E2 cells as the AD cell model. 20E2 cells were treated with orexin-A (50, 100 nmol/L). The effect of different concentrations of orexin-A on cell activity was detected by MTT. As compared with the non-treated 20E2 cells, orexin-A-treated 20E2 cells showed increased expression of APP, decreased cell viability and decreased adenosine triphosphate (ATP) level, decreased levels of regulatory proteins of mitochondrial biogenesis (peroxisome proliferator-activated receptor gamma coactivator 1-alpha [PGC-1α], nuclear respiratory factor 1/2 [NRF1/2], mitochondrial transcription factor A [TFAM]), increased levels of regulatory proteins of mitophagy (Parkin, PTEN-induced putative kinase 1 [PINK1], microtubule-associated protein light chain 3 II/I [LC3-II/LC3-I]) and decreased p62 level, with damaged mitochondrial structure. Orexin-A may reduce mitochondrial biogenesis, enhance mitophagy and damage mitochondrial structure in AD.Entities:
Keywords: Alzheimer's disease; HEK293-APPswe cells; mitochondrial biogenesis; mitophagy; orexin-A
Mesh:
Substances:
Year: 2021 PMID: 33080054 DOI: 10.1111/1440-1681.13424
Source DB: PubMed Journal: Clin Exp Pharmacol Physiol ISSN: 0305-1870 Impact factor: 2.557